NCT00126607

Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer

Public trial-level signal summary for this oncology Phase 2 record.

Record overview

Status and phase

Status: TERMINATED

Phase: PHASE2

Sponsor: National Cancer Institute (NCI)

Condition: High-grade Salivary Gland Mucoepidermoid Carcinoma, Recurrent Salivary Gland Cancer, Salivary Gland Acinic Cell Tumor, Salivary Gland Adenocarcinoma, Salivary Gland Poorly Differentiated Carcinoma, Stage IVA Salivary Gland Cancer, Stage IVB Salivary Gland Cancer, Stage IVC Salivary Gland Cancer

Signal summary

Public flags

Status signal: Registry Stop Signal

Timeline signals: stale_update_signal

Results signal: Low Signal

Operational burden: strict_eligibility_signal

Stopped reason

Context when available

Poor accrual.